A phase II study to evaluate the safety and efficacy of anlotinib combined with toripalimab for advanced biliary cancer.

被引：0
|
作者：
Shen, Jie
Kong, Weiwei
Zhu, Sihui
Liu, Baorui
机构：
[1] Nanjing Univ, Affiliated Drum Tower Hosp, Med Sch, Nanjing, Peoples R China
[2] Nanjing Univ, Comprehens Canc Ctr, Drum Tower Hosp, Med Sch, Nanjing, Peoples R China
[3] Nanjing Univ, Clin Canc Inst, Nanjing, Peoples R China
[4] Nanjing Univ, Comprehens Canc Ctr, Med Sch, Clin Canc Inst,Drum Tower Hosp, Nanjing, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4077
引用
收藏
页数：1
相关论文
共 50 条
  • [31] A phase II study to evaluate the efficacy and safety of fruquintinib combined with tislelizumab and Hepatic Artery Infusion Chemotherapy (HAIC) for advanced Colorectal Cancer Liver Metastases (CRLM)
    Wang, L.
    Zhang, T.
    Zhao, Y.
    Pan, Q.
    Mao, A.
    Zhu, W.
    Feng, Y.
    Zhou, J.
    ANNALS OF ONCOLOGY, 2023, 34 : S451 - S451
  • [32] A phase II study of gastrimmune in advanced pancreatic cancer.
    Brett, BT
    Smith, SC
    Bouvier, CV
    Michaeli, D
    Hochhauser, D
    Davidson, BR
    Kurzawinski, TR
    Watkinson, T
    Van-Someren, N
    Pounder, RE
    Caplin, ME
    GASTROENTEROLOGY, 2000, 118 (04) : A642 - A642
  • [33] Updated results from the phase II study: Efficacy and safety of anlotinib plus sintilimab as second-line treatment for patients with advanced biliary tract cancers.
    Jin, Shuiling
    Zhao, Ruihua
    Zhou, Chuang
    Zhong, Qian
    Zhang, Xiaojian
    Zong, Hong
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 577 - 577
  • [34] Phase I study to evaluate the safety and efficacy of rivoceranib (apatinib) and nivolumab in patients with unresectable or metastatic cancer.
    Chawla, Sant P.
    Chua, Victoria S.
    Gordon, Erlinda Maria
    Moradkhani, Ania
    Kim, Katherine
    Quon, Doris
    Wong, Steven
    Sumner, Robert
    Mac, Virginia
    Huang, Raymond
    Wang, Kelly
    Kim, Jiyeun
    Kim, Bumjin
    McGinn, Arlo N.
    Park, Cheol Hee
    Houston, Scott
    Sankar, Neil
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (08)
  • [35] The Efficacy and Safety of Anlotinib in Neoadjuvant Treatment of Locally Advanced Thyroid Cancer: A Single-Arm Phase II Clinical Trial
    Huang, Nai-si
    Wei, Wen-jun
    Xiang, Jun
    Chen, Jia-ying
    Guan, Qing
    Lu, Zhong-wu
    Ma, Ben
    Sun, Guo-hua
    Wang, Yu-long
    Ji, Qing-hai
    Wang, Yu
    THYROID, 2021, 31 (12) : 1808 - 1813
  • [36] EFFICACY AND SAFETY OF ANLOTINIB COMBINED WITH ICOTINIB IN THE TREATMENT OF ADVANCED NON-SMALL-CELL LUNG CANCER
    Chen, Hualin
    Luo, Yiping
    Lin, Muwen
    Peng, Xiaoxia
    Liu, Meilian
    Huang, Zhong
    Wang, Yongcun
    Li, Shujun
    Yang, Donghong
    Yang, Zhixiong
    ACTA MEDICA MEDITERRANEA, 2022, 38 (03): : 2035 - 2040
  • [37] Efficacy and safety of anlotinib with PD-1 blockades in the treatment of advanced biliary tract cancer: A real-world study.
    Chen, Kehe
    Huang, Xianshi
    Yu, Lei
    Hou, Encun
    Ou, Mei
    Wang, Junping
    Huang, Xiao
    Pan, Deng
    Liu, Yu
    Huang, Min
    Zhong, Wenhe
    Pan, Zhuang
    Zhang, Shijie
    Li, Bin
    Nong, Xiansheng
    Chen, Kefan
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E16129 - E16129
  • [38] Efficacy and safety of PD-1 inhibitor combined with anlotinib in the treatment of advanced
    Song, L.
    Yu, X.
    JOURNAL OF NEUROENDOCRINOLOGY, 2021, 33 : 145 - 145
  • [39] The efficacy and safety of anlotinib combined with chemotherapy in treatment of advanced soft tissue sarcoma
    Ni, Ying
    Dong, Yabing
    Jiang, Aijun
    Zhang, Qun
    Wang, Zhantong
    Liang, Hui
    Zhang, Wei
    DISCOVER ONCOLOGY, 2024, 15 (01)
  • [40] R-IMMUNE: A phase Ib/II study to evaluate safety and efficacy of atezolizumab combined with radiochemotherapy in a preoperative setting for patients with locally advanced rectal cancer (LARC)
    Carrasco, J.
    Beniuga, G.
    Jouret-Mourin, A.
    Baldin, P.
    Sinapi, I.
    Schroeder, D.
    De Cuyper, A.
    Sclafani, F.
    Hendlisz, A.
    van Laethem, J-L.
    Boulanger, A-S.
    Van Ooteghem, G.
    Dermine, A.
    Delmarcelle, S.
    Huyghe, N.
    Bar, I.
    van den Eynde, M.
    ANNALS OF ONCOLOGY, 2023, 34 : S432 - S432
12345